Calliditas Therapeutics AB
Calliditas Therapeutics AB (CALT): 3 pipeline candidates · ~385 mo cash runway · 8 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
385.2 months
0% dilution
Lead: Phase 2
3 candidates
N/A
N/A
A transparent, data-derived signal for Calliditas Therapeutics ABacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$797.3M
Quarterly Burn
$7.0M
Runway
385.2 mo
Revenue
$559.8M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
Frequently asked questions
How many drug candidates are in Calliditas Therapeutics AB's pipeline?
Calliditas Therapeutics AB (CALT) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Calliditas Therapeutics AB's lead drug candidate?
Calliditas Therapeutics AB's most advanced tracked candidate is GKT137831 (Phase 2) for Type 2 Diabetes Mellitus With Diabetic Nephropathy.
What is Calliditas Therapeutics AB's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Calliditas Therapeutics AB has approximately 385.2 months of cash runway.
Get the full picture on Calliditas Therapeutics AB
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.